Despite Boston Scientific’s success claims, an independent review of clinical data by the Wall St. Journal shows that the stent has significant flaws. Boston Scientific’s Taxus Liberte already enjoys strong sales abroad but is in the midst of seeking approval by the FDA. The Journal’s analysis, “Boston Scientific’s claim was based on a flawed statistical equation that favored the Liberte stent.” The equation known as the Wald interval has been criticized for exaggerating the certainty of research results. According to the Journal article, rival stent makers Abbott Laboratories and Medtronic Inc. have used the same equation in order to leverage research results in their favor. The Wall St. Journal noted the less rigorous nature of approving medical devices as opposed to pharmaceutical drugs.